INTRODUCTION AND OBJECTIVES:
Canine bladder cancer provides a novel model system for the study of invasive human urothelial carcinoma. The immunobiology of canine tumors is largely unknown. We report the first evaluation of immune checkpoint B7x, a major contributor to T-cell co-inhibition in human bladder cancers, in primary canine urothelial neoplasms.
METHODS: With approval of the Purdue Animal Care and Use Committee, dogs with spontaneous bladder cancer were identified and tumor specimens were collected by cystoscopic biopsy from treatmentnaive dogs. Normal bladder tissue was collected from dogs that were being euthanized for conditions other than bladder-related diseases. RNA-seq data from 29 canine invasive bladder tumors and 4 normal bladders were used to determine B7x expression. Gene ontology analysis was performed to explore the biological role of B7x. A set of 50 canine bladder tumor samples and 4 normal bladder tissues were evaluated for B7x protein by IHC and corresponding clinicopathologic data was obtained from chart review. TCGA and GTEx were used to examine B7x expression in 599 human urothelial tumors (BLCA).
RESULTS: Of the 50 canine urothelial tumors, 47 (94%) were stage pT2 or higher and 43 (86%) were non-metastatic. In the RNA-seq analysis, B7x expression in the tumors was 5.72 and 7.04 fold upregulated, respectively, using DESeq2 and edge R (Figure 1 ). IHC analysis revealed 30 of 50 cases (60%) as positive for B7x expression. B7x intensity was scored as negative in 40% (n[20/50), low in 24% (n[12/50), medium in 14% (n[7/50) and high in 22% (n[11/50) of cases (an example of high B7x expression is seen in Figure 2 ). There was no correlation between B7x expression and clinicopathologic characteristics. B7x expression was closely associated with immune processes in gene ontology analysis. In human BLCA, B7x expression was significantly associated with worse overall survival (p[0.02).
CONCLUSIONS: Our results suggest that B7x is highly expressed in canine bladder cancer, which is a tumor model that is vital to advancing the translational research on B7x, a new potential therapeutic target in human bladder cancer.
INTRODUCTION AND OBJECTIVES: Trimodality bladdersparing therapy has become an accepted treatment for selected patients with muscle-invasive bladder cancer (MIBC). As the presence of hydronephrosis may reduce complete response rate as well as survival in trimodality therapy, some investigators deem hydronephrosis as a contraindication for bladdersparing. We have developed a tetra-modality bladder-sparing therapy (TeMT) consisting of maximal transurethral resection (TUR), induction chemoradiotherapy (CRT), and partial cystectomy (PC) (Koga et al, BJU Int 2012) . TeMT which enables surgical consolidation of original MIBC site, involving uretero-vesical anastomosis if necessary, may provide more chance of bladder-sparing for patients with hydronephrosis.
METHODS: A total of 151 consecutive patients with cT2-3N0M0 MIBC (median age 69, female/male [ 33/118, cT2/3 [ 100/51) entered tetra-modality bladdersparing protocol. After maximal TUR and CRT (40Gy þ cisplatin), response was evaluated by cytology, imaging and tumor-site rebiopsy. Complete responders proceeded to consolidative PC, while radical cystectomy was recommended for others. Extension of ipsilateral intrapelvic ureter in pretreatment computed tomography was graded following the Society for Fetal Urology grading system, then patients with grade 2-3 were classified as with hydronephrosis. Response rate to CRT, MIBC recurrence-free survival and cancer-specific survival (CSS) were compared between patients with or without hydronephrosis.
RESULTS: Hydronephrosis was found in 19 patients (14%), and was associated with lower response rate to CRT (42% in hydronephrosis vs 77% in normal, p[0.03) . On an intent-to-treat basis, patients with hydronephrosis (n[19) had lower 5-yr CSS than those without it (n[132) (62% vs 85%, p<0.01; Fig. A) . Among the 106 patients who completed PC on protocol, 24 patients underwent uretero-vesical anastomosis. In the patients on protocol, patients with (n[9) and without hydronephrosis (n[97) had comparable 5-yr MIBS recurrence-free survival (100% vs 97%, p[0.11) and CSS (100% vs 93%, p[0.46; Fig. B) .
CONCLUSIONS: Patients with hydronephrosis should not necessarily be excluded from tetra-modality bladdersparing therapy. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e443
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